Sarepta Therapeutics Inc (NAS:SRPT)
$ 121.5 -1.87 (-1.52%) Market Cap: 11.61 Bil Enterprise Value: 11.98 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 86/100

Sarepta Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 05:40PM GMT
Release Date Price: $118.47 (-1.91%)
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Well, good morning, everyone. Thanks for joining us. I'm Salveen Richter, one of the biotechnology analysts here at Goldman Sachs. We're pleased to have the Sarepta team with us today, and we have Doug Ingram, President and CEO.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

So with that, Doug, you know, we've seen a rapid evolution of Sarepta over the past year and you're now positioned as a leader with multiple platforms to address neuromuscular diseases with genomic medicine, could you -- and RNA medicines as well. Can you just walk us through how you think about the next 5 years for Sarepta?

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Sure. I should say, in fairness to our lawyers they are happy, that we -- obviously, this is a perfect example. I'll be making some forward-looking statements and obviously, I would ask people to look to our public

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot